We advised Turn Therapeutics on its Nasdaq listing

Davis Polk advised Turn Therapeutics Inc. in connection with the direct listing of its common stock on the Nasdaq Global Market. Turn Therapeutics’ common stock is listed under the symbol “TTRX.”

Turn Therapeutics is a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Its patented mixing process enables stable suspension of polar, water-soluble active pharmaceutical ingredients in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.

The Davis Polk capital markets team included partners Michael Kaplan and Stephen A. Byeff and associates Kanger Jin, Megan P. Phansalkar and Kristiana J. Olson. Partner David R. Bauer and associate Francesca Masella provided intellectual property advice. Partner Travis Triano provided executive compensation advice. The tax team included partner Kara L. Mungovan and associate Alanna Phillips. All members of the Davis Polk team are based in the New York office.

Copy link to share post